{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:11:12Z","timestamp":1788948672382,"version":"build-2803163510"},"reference-count":33,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background\/Objective: Intradetrusor onabotulinumtoxinA is an established treatment for refractory idiopathic overactive bladder (OAB); however, data on predictors of treatment response and patient management after the initial injection are limited. This study evaluated the clinical outcomes, safety, factors associated with treatment failure, and retreatment pathways following intradetrusor onabotulinumtoxinA in women with refractory idiopathic OAB. Methods: This retrospective cohort study included 41 women with refractory idiopathic OAB treated with 100 U intradetrusor onabotulinumtoxinA between November 2022 and January 2026. Efficacy was assessed using 3-day bladder diaries, validated patient-reported outcome measures (UDI-6, IIQ-7, and OAB-V8), and the Treatment Benefit Scale (TBS). Safety outcomes, factors associated with treatment failure, retreatment preferences, and subsequent management strategies were analyzed. Results: Significant improvements were observed in daytime frequency, urgency episodes, urgency urinary incontinence episodes, and validated patient-reported outcome measures (all p &lt; 0.001). Treatment success according to the TBS was achieved in 68.3% and 46.3% of patients at 12 and 24 weeks, respectively. Diffuse bladder trabeculation was independently associated with treatment failure at 12 weeks (aOR 11.90, 95% CI 1.99\u201371.14; p = 0.007), whereas no significant independent association was observed at 24 weeks. Urinary tract infection occurred in 19.5% of patients, and temporary clean intermittent catheterization was required in one patient (2.4%). By postoperative week 24, 53.7% of patients declined repeat treatment, most commonly because of inadequate symptom improvement (77.3%). Among those declining reinjection, 59.1% resumed or continued pharmacological therapy. Conclusions: Intradetrusor injection of 100 U onabotulinumtoxinA was associated with significant improvement and acceptable safety in women with refractory idiopathic OAB. Diffuse bladder trabeculation may help identify patients at risk of poor treatment response, warranting further validation in larger patient cohorts. Documenting retreatment decisions and management provides real-world evidence that may support long-term counseling and decision-making.<\/jats:p>","DOI":"10.3390\/jcm15186977","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T09:24:02Z","timestamp":1788945842000},"page":"6977","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Outcomes and Retreatment Pathways Following Intradetrusor OnabotulinumtoxinA in Women with Refractory Idiopathic Overactive Bladder"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-9101","authenticated-orcid":false,"given":"Reyyan","family":"G\u00f6k\u00e7en \u0130\u015fcan","sequence":"first","affiliation":[{"name":"Department of Gynecology and Obstetrics, Zeynep Kamil Women and Children Diseases Training and Research Hospital, University of Health Sciences, Istanbul 34668, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"}]},{"given":"M\u00fc\u015ferref Banu","family":"Y\u0131lmaz","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Zeynep Kamil Women and Children Diseases Training and Research Hospital, University of Health Sciences, Istanbul 34668, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"}]},{"given":"B\u00fc\u015fra","family":"Bucak","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Zeynep Kamil Women and Children Diseases Training and Research Hospital, University of Health Sciences, Istanbul 34668, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"data-curation","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8385-5431","authenticated-orcid":false,"given":"\u00d6nder","family":"Tosun","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Zeynep Kamil Women and Children Diseases Training and Research Hospital, University of Health Sciences, Istanbul 34668, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"}]},{"given":"Mine","family":"G\u00fcray Uzun","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Zeynep Kamil Women and Children Diseases Training and Research Hospital, University of Health Sciences, Istanbul 34668, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"}]},{"given":"Sultan Seren","family":"Karaku\u015f","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Zeynep Kamil Women and Children Diseases Training and Research Hospital, University of Health Sciences, Istanbul 34668, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"}]},{"given":"P\u0131nar","family":"Kumru","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Zeynep Kamil Women and Children Diseases Training and Research Hospital, University of Health Sciences, Istanbul 34668, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"supervision","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00192-009-0976-9","article-title":"An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction","volume":"21","author":"Haylen","year":"2010","journal-title":"Int. Urogynecol. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s00192-024-06029-2","article-title":"Global Prevalence of Overactive Bladder: A Systematic Review and Meta-analysis","volume":"36","author":"Zhang","year":"2025","journal-title":"Int. Urogynecol. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","article-title":"OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: A randomised, double-blind, placebo-controlled trial","volume":"64","author":"Chapple","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"593","DOI":"10.31128\/AJGP-11-19-5142","article-title":"Overactive bladder syndrome: Management and treatment options","volume":"49","author":"Hutchinson","year":"2020","journal-title":"Aust. J. Gen. Pract."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2022.01.045","article-title":"European Association of Urology Guidelines on the Diagnosis and Management of Female Non-neurogenic Lower Urinary Tract Symptoms. Part 1: Diagnostics, Overactive Bladder, Stress Urinary Incontinence, and Mixed Urinary Incontinence","volume":"82","author":"Nambiar","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/nau.25532","article-title":"The AUA\/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder","volume":"43","author":"Cameron","year":"2024","journal-title":"Neurourol. Urodyn."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1002\/nau.24936","article-title":"Barriers and facilitators to overactive bladder therapy adherence","volume":"41","author":"Enemchukwu","year":"2022","journal-title":"Neurourol. Urodyn."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s00345-026-06471-5","article-title":"Navigating the challenges of overactive bladder management in women","volume":"44","author":"Braga","year":"2026","journal-title":"World J. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.32604\/cju.2025.064912","article-title":"Botulinum toxin A in idiopathic overactive bladder: A narrative review of 5410 cases","volume":"32","author":"Lachkar","year":"2025","journal-title":"Can. J. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.juro.2012.12.022","article-title":"OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: Results of a phase 3, randomized, placebo controlled trial","volume":"189","author":"Nitti","year":"2013","journal-title":"J. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/nau.23286","article-title":"Efficacy and safety of onabotulinumtoxinA injection in patients with refractory overactive bladder: First multicentric study in Turkish population","volume":"37","author":"Onem","year":"2018","journal-title":"Neurourol. Urodyn."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Enemchukwu, E., Mohamud, H., Sinclair, S., Harbour, V., Syan, R., Kennelly, M., and Gunamany, S. (2025). Intravesical Onabotulinum Toxin A Injection Paradigms for Idiopathic Overactive Bladder: A Scoping Review of Clinical Outcomes, Techniques, and Implications for Practice and Future Research. Toxins, 17.","DOI":"10.3390\/toxins17050211"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/nau.20292","article-title":"Validation of the short forms of the incontinence impact questionnaire (IIQ-7) and the urogenital distress inventory (UDI-6) in a Turkish population","volume":"26","author":"Cam","year":"2007","journal-title":"Neurourol. Urodyn."},{"key":"ref_14","first-page":"113","article-title":"OAB V8 A\u015f\u0131r\u0131 aktif mesane sorgulama formu validasyon \u00e7al\u0131\u015fmas\u0131","volume":"21","author":"Tarcan","year":"2012","journal-title":"Urol. B\u00fcl."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.urology.2008.05.033","article-title":"Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder","volume":"72","author":"Colman","year":"2008","journal-title":"Urology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/bju.13945","article-title":"Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: A systematic review and network meta-analysis","volume":"120","author":"Drake","year":"2017","journal-title":"BJU Int."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1007\/s11255-015-1125-7","article-title":"The safety and efficiency of onabotulinumtoxinA for the treatment of overactive bladder: A systematic review and meta-analysis","volume":"47","author":"Sun","year":"2015","journal-title":"Int. Urol. Nephrol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1208872","article-title":"Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence","volume":"367","author":"Visco","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00192-020-04423-0","article-title":"OnabotulinumtoxinA is a well tolerated and effective treatment for refractory overactive bladder in real-world practice","volume":"32","author":"Hamid","year":"2021","journal-title":"Int. Urogynecol. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.juro.2016.03.146","article-title":"Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study","volume":"196","author":"Nitti","year":"2016","journal-title":"J. Urol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00192-023-05665-4","article-title":"Antibiotic prophylaxis for onabotulinum toxin A injections: Systematic review and meta-analysis","volume":"35","author":"Getaneh","year":"2024","journal-title":"Int. Urogynecol. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1002\/nau.25538","article-title":"Efficacy and safety of onabotulinumtoxinA for the treatment of overactive bladder in men and women: A pooled analysis","volume":"43","author":"Nitti","year":"2024","journal-title":"Neurourol. Urodyn."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/sj.sc.3101318","article-title":"Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity","volume":"40","author":"Wyndaele","year":"2002","journal-title":"Spinal Cord"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.euf.2020.06.013","article-title":"Predictors of Poor Response and Adverse Events Following Botulinum Toxin A for Refractory Idiopathic Overactive Bladder: A Systematic Review","volume":"7","author":"Abrar","year":"2021","journal-title":"Eur. Urol. Focus"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00192-025-06047-8","article-title":"Efficacy of 100-U Onabotulinumtoxin A Treatment in Female Idiopathic Overactive Bladder-A Prospective Follow-Up Study","volume":"36","author":"Nurkkala","year":"2025","journal-title":"Int. Urogynecol. J."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Fusco, F., Creta, M., De Nunzio, C., Iacovelli, V., Mangiapia, F., Li Marzi, V., and Agr\u00f2, E.F. (2018). Progressive bladder remodeling due to bladder outlet obstruction: A systematic review of morphological and molecular evidences in humans. BMC Urol., 18.","DOI":"10.1186\/s12894-018-0329-4"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/S0022-5347(05)67727-0","article-title":"Voiding cystourethrography findings in elderly women with urge incontinence","volume":"163","author":"Fielding","year":"2000","journal-title":"J. Urol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00192-012-1989-3","article-title":"Clinical findings associated with bladder trabeculations in women","volume":"24","author":"Gowda","year":"2013","journal-title":"Int. Urogynecol. J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4103\/abr.abr_393_14","article-title":"Is there any Relationship Between Bladder Trabeculation and Efficacy and Safety of Intravesical Botulinum Toxin A Injection in Refractory Idiopathic Overactive Bladder Women?","volume":"6","author":"Zargham","year":"2017","journal-title":"Adv. Biomed. Res."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Jankovic, J., Carruthers, J., Naumann, M., Ogilvie, P., Boodhoo, T., Attar, M., Gupta, S., Singh, R., Soliman, J., and Yushmanova, I. (2023). Neutralizing Antibody Formation with OnabotulinumtoxinA (BOTOX\u00ae) Treatment from Global Registration Studies across Multiple Indications: A Meta-Analysis. Toxins, 15.","DOI":"10.3390\/toxins15050342"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1464-410X.2012.11282.x","article-title":"Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB)","volume":"111","author":"Mohee","year":"2013","journal-title":"BJU Int."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00345-016-1862-y","article-title":"Long-term follow-up of intravesical botulinum toxin-A injections in women with idiopathic overactive bladder symptoms","volume":"35","author":"Marcelissen","year":"2017","journal-title":"World J. Urol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.eururo.2011.12.011","article-title":"Repeated botulinum toxin type A injections for refractory overactive bladder: Medium-term outcomes, safety profile, and discontinuation rates","volume":"61","author":"Dowson","year":"2012","journal-title":"Eur. Urol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/18\/6977\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T09:59:21Z","timestamp":1788947961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/18\/6977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":33,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jcm15186977"],"URL":"https:\/\/doi.org\/10.3390\/jcm15186977","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]}}}